|1.||Parren, Paul W H I: 4 articles (01/2012 - 10/2008)|
|2.||Bleeker, Wim K: 3 articles (05/2014 - 01/2010)|
|3.||van de Winkel, Jan G J: 3 articles (09/2011 - 10/2008)|
|4.||Lammerts van Bueren, Jeroen J: 3 articles (09/2011 - 10/2008)|
|5.||Lisby, Steen: 2 articles (06/2014 - 04/2011)|
|6.||Houtkamp, Mischa: 2 articles (05/2014 - 01/2012)|
|7.||van den Brakel, Jeroen H: 2 articles (05/2014 - 09/2011)|
|8.||Saloura, Vassiliki: 1 article (06/2014)|
|9.||Licitra, Lisa: 1 article (06/2014)|
|10.||Gauler, Thomas C: 1 article (06/2014)|
05/01/2014 - "(111)In-labeled zalutumumab, a human monoclonal human EGFr-targeting antibody, was administered at a nonsaturating dose to 3 mice with xenografted A431 tumors exhibiting high EGFr expression. "
09/15/2011 - "Finally, tumor growth of mutant KRAS-expressing A431 tumor cells, which were resistant to EGFR signaling inhibition, was completely prevented by early treatment with zalutumumab and mAb 018, whereas ADCC-crippled N297Q-mutated variants of both mAbs did not show any inhibitory effects. "
09/15/2011 - "Interestingly, however, both zalutumumab and mAb 018 prevented tumor formation upon early treatment in this model. "
01/01/2010 - "In the low-dose model, zalutumumab and panitumumab similarly prevented tumor growth. "
10/01/2008 - "We depict how our science-based approach can be used to further improve the efficacy of antibody therapeutics, illustrated by the development of three monoclonal antibodies for various cancer indications: zanolimumab (directed against CD4), ofatumumab (directed against CD20) and zalutumumab (directed against epidermal growth factor receptor)."
|2.||Head and Neck Neoplasms (Head and Neck Cancer)
01/01/2012 - "Current data from Phase I and II trials identify zalutumumab as a promising drug for the treatment of locally advanced head and neck cancer and recent data from a Phase III randomized trial showed encouraging survival results compared with best supportive care. "
01/01/2012 - "The mechanism of action and data on efficacy and safety of zalutumumab in head and neck cancer. "
01/01/2012 - "Zalutumumab in head and neck cancer."
01/01/2012 - "Zalutumumab has demonstrated acceptable toxicity in head and neck cancer patients, with rash being the most common adverse event. "
06/01/2010 - "The search terms included 'head and neck cancer', 'EGFR', 'cetuximab', 'panitumumab', 'zalutumumab', 'nimotuzumab', 'erlotinib', 'gefitinib' and 'lapatinib'. "
|3.||Squamous Cell Neoplasms (Squamous Cell Cancer)
|4.||Colorectal Neoplasms (Colorectal Cancer)
06/01/2014 - "Patients received weekly infusions of zalutumumab individually titrated to a grade 2 skin rash. "
04/01/2011 - "Zalutumumab dose titration on the basis of rash is safe. "
04/01/2011 - "Zalutumumab was given weekly by individual dose titration on the basis of skin rash. "
01/01/2012 - "Here, we developed a model for induction of papulopustular rash in healthy human volunteers by subcutaneous injection of the anti-EGFR monoclonal antibody zalutumumab. "
06/01/2014 - "Grade 3-4 adverse events related to zalutumumab were observed in 19 % of patients and included skin rash (5 %), hypomagnesemia (4 %) and pneumonitis (1 %). "
|1.||Epidermal Growth Factor Receptor (EGF Receptor)